Author of

• 15558

  +

  P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Small Cell Lung Cancer
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15570

    +

    P3.07-012 - Hiperfracctioned Radiochemotherapy in Small Cell Lung Cancer, a Monoinstutional Experience (ID 2567)

    09:30 - 09:30  |  Author(s): P. Calvo Crespo
    • Abstract
    • Slides

    Background:
    To evaluate our experience in radical radiochemotherapy (RCT) twice daily in limited disease small cell lung cancer (SCLC) in term of effectiveness and toxicity.
    
    Methods:
    A retrospective review was performed to determine the local recurrence and survival rates for patients with SCLC localized disease undergoing RCT according Turrisi regimen between October 2004 and August 2014. All patients were treated with 3DRT, with a median dose of 45 Gy (150cGy twice daily), combined with chemotherapy based in cisplatinum-VP16. 73% received preventive cranial irradiation (ICP). 22% of patients underwent induction QT based in platinum-VP16. The primary objective was overall survival (OS); secondary objectives were progression free survival (PFS), local progression free survival (LPFS) and toxicity. OS was analized with Kaplan-Meier test.
    
    Results:
    44 elegible patients were recruited (82% male, median age 62, with good performance status). The clinical stage was 89% E.III and 11% E.II. At a median follow-up of 18 months, the median OS was 21 months (95%CI: 16.3-25.4) and median PFS was 12.6 months (95%CI: 10.2-15). OS at 2 and 5 years were 38.6% and 24.8% respectively. LPFS was 14 months (95%CI: 10.5 -17.6) and systemic progression free survival was 14.2 (95%CI:10.1-18.2). During the RCT we reported anaemia (2%G3), neutropenia (7%G3, 16%G4), esophagitis (2%G3), dyspnea (2%G2), pneumonitis (7%G2). Induction QT did not improve the OS and PFS.
    
    Conclusion:
    In our experience radical radiochemotherapy twice daily is a feasible treatment option for small cell lung cancer, showing long-term survival with no inferiority results compared with the published and acceptable toxicities.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.